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a b s t r a c t
Vitamin D deficiency (VDD) is highly prevalent worldwide. The classical role for vitamin D is to regulate
calcium absorption form the gastrointestinal tract and influence bone health. Recently vitamin D re-
ceptors and vitamin D metabolic enzymes have been discovered in numerous sites systemically sup-
porting diverse extra-skeletal roles of vitamin D, for example in asthmatic disease. Further, VDD and
asthma share several common risk factors including high latitude, winter season, industrialization, poor
diet, obesity, and dark skin pigmentation.
Vitamin D has been demonstrated to possess potent immunomodulatory effects, including effects on T
cells and B cells as well as increasing production of antimicrobial peptides (e.g. cathelicidin). This
immunomodulation may lead to asthma specific clinical benefits in terms of decreased bacterial/viral
infections, altered airway smooth muscle-remodeling and efunction as well as modulation of response
to standard anti-asthma therapy (e.g. glucocorticoids and immunotherapy).
Thus, vitamin D and its deficiency have a number of biological effects that are potentially important in
altering the course of disease pathogenesis and severity in asthma. The purpose of this first of a two-part
review is to review potential mechanisms whereby altering vitamin D status may influence asthmatic
disease.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Asthma is a disease characterized by variable airway obstruc-
tion, respiratory symptoms, bronchial hyper-responsiveness and
airway inflammation [40]. It represents a major public health
problem, affecting ~300 million people worldwide [164]. Due its
prevalence, asthma costs the US health care system an estimated
$56 billion annually [17].
The exact cause of asthma remains unknown. For reasons not
completely understood, asthma prevalence and severity has
increased markedly since the ~1960s [39,69]. Further, asthma
prevalence continues to increase in both children and adults and
across ethnicities [164,178]. However, this increase does appear
related to industrialization [9,38,164,229] and increased adiposity
[23,221,231]. Additionally, asthma seems to be more prevalent at
higher latitude [117,134]. Furthermore, the severity of asthma
symptoms appears related to winter season [117,129,221] and
darker skin pigmentation [9,102,121,177,187]. Finally, asthma is
associated with exposure to cigarette smoke [103,254], pollution
[190,278] and physical inactivity [256]. Although there is a complex
interaction between these factors and asthma pathogenesis, one
hypothesis that could potentially partially explain these associa-
tions is vitamin D deficiency (VDD).
This first part of a two-part review will introduce vitamin D
metabolism and physiology. However, the main focus will be an
exploration of the diverse mechanisms by which vitamin D may
influence asthmatic disease. We have reviewed the evidence link-
ing vitamin D and asthmatic disease from human studies in part
two of this review [127].
2. Methods
References were identified by searches of MEDLINE, CINAHL,
EMBASE and online Cochrane databases through January 2015.
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Keywords used included vitamin D and asthma, wheezing, airway
inflammation, airway smooth muscle, and respiratory infection.
Only manuscripts published in English are included. Articles were
chosen according to their relevance for this review and their bib-
liographies were also searched for further references.
3. Results and discussion
3.1. Metabolism & physiology of vitamin D
Vitamin D can be described as a pre-prohormone. Vitamin D,
either orally ingested or from ultraviolet B (UV-B) exposure is
mostly inactive and must be dihydroxylated to its metabolically
active form: 1,25-dihydroxyvitamin D (1,25D), also known as cal-
citriol. In the first step vitamin D is hydroxylated in the liver to form
25-hydroxyvitamin D (25(OH)D), also known as calcidiol. 25(OH)D
is the storage form of vitamin D, which reliably indicates systemic
vitamin D status [94,105,106]. The second hydroxylation to produce
1,25D occurs primarily in the kidney, but also extrarenally [99,282].
Unlike extrarenal production of 1,25, renal production of 1,25D is
tightly regulated by serum levels of parathyroid hormone, calcium
and phosphorus. However, tissue and intracellular 1,25 regulation
is independent of serum 25(OH)D levels [151,222]. 1,25D has sys-
temic endocrine, paracrine and autocrine effects.
3.1.1. 1a-hydroxylase
Animal and human studies demonstrate that the enzyme
responsible for the second hydroxylation (1a-hydroxylase or
CYP27B1) i.e. converting 25(OH)D into active 1,25D is present in
many immune cells such as macrophages [83,151,193,194],
including monocytes [132]; pulmonary alveolar macrophages [3], T
cells [290], B cells [51] and dendritic cells [100,232] as well as many
sites relevant to asthma for example lung fibroblasts [189], airway
smooth muscle cells [15] and airway epithelial cells [91]. The
presence of 1a-hydroxylase at these sites enables local hydroxyl-
ation of 25(OH)D into 1,25D and potentially enables high concen-
trations of 1,25D to increase the expression of vitamin D regulated
genes with important immune functions. This however, depends
on substrate availability (i.e. 25(OH)D). Supporting active hydrox-
ylation of 25(OH)D to 1,25D in atopy/asthma airways, it has
recently been demonstrated that 1,25D levels were low in airways
but increased after allergen challenge and the increase correlated
Abbreviations list
1,25D 1,25-dihydroxyvitamin D
25(OH)D 25-hydroxyvitamin D
AAR allergic rhinitis þ allergic asthma
ACT asthma control test
AMP antimicrobial peptide
AR allergic rhinitis
ASM airway smooth muscle
BALF bronchoalveolar lavage fluid
BMD bone mineral density
BMI body mass index
CI confidence interval
COX-2 cyclooxygenase-2
CRTAM class I MHCerestricted T celleassociated molecule
gene
d day
DBRCT double-blind, randomized, placebo controlled trial
DC dendritic cell
FoxP3 forkhead box P3
GCS glucocorticoids
GM-CSF granulocyte macrophage colony-stimulating factor
h hour
H2O2 hydrogen peroxide
HBECs human bronchial epithelial cells
hCAP-18 human cathelicidin antimicrobial peptide-18
ICS inhaled corticosteroid
IFN g interferon gamma
IgE immunoglobulin E
IgG immunoglobulin G
IL interleukin
IL1RL1 interleukin 1 receptor-like 1
IP-10 interferon gamma-induced protein 10 is a protein that
in humans is encoded by the CXCL10 gene and is a
small cytokine belonging to the CXCchemokine family.
IU international unit
LL-37 the protein precursor to hCAP-18 which undergoes
extracellular cleavage to generate a 37-residue active
cationic peptide
LPS lipopolysaccharides
MAP mitogen-activated protein
MKP-1 mitogen-activated protein kinase 1
NF-kB nuclear factor kappa-light-chain-enhancer of activated
B cells
NK natural killer
OCS oral corticosteroid
OR odds ratio
PBMCs peripheral blood mononuclear cells
PGE2 prostaglandin E2
RANTES regulated on activation, normal T cell expressed and
secreted. RANTES is also known as Chemokine (CeC
motif) ligand 5 (also CCL5).
RORC retinoid-related orphan receptor C
ROS reactive oxygen species
RSV respiratory syncytial virus
RTI respiratory tract infection
RXRa retinoid X receptor-a
SIT specific immunotherapy
SNP single nuclear polymorphism
SR steroid resistant
SS steroid sensitive
sST2 soluble decoy receptor for Il-33
T-regs regulatory T cells
TGF transforming growth factor
Th T helper
TLRs the toll-like receptors
TNF-a tumor necrosis factor alpha
UV-B ultraviolet-B radiation
VDBP vitamin D binding protein
VDD vitamin D deficiency
VDI vitamin D insufficiency
VDR vitamin D receptor
VDRE vitamin D response element
WBCs white blood cells
gd T cells gamma delta T cells
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with the inflammatory response and increases in cathelicidin [149]
e see section 3.2.3.1.
3.1.2. Vitamin D receptor
The vitamin D receptor (VDR) is a member of the steroid re-
ceptor superfamily. Over 3000 genes are responsive to 1,25D [29]
and its biological effects are mediated through binding to the
VDR and inducing either genomic or non-genomic effects [59,182].
Upon 1,25D binding, VDR translocates from the plasma membrane
to the nucleus where it transcriptionally activates genes via the
vitamin D response element (VDRE), thereby affecting transcription
of other genes [59]. VDR interacts with multiple proteins including
the retinoid X receptor-a (RXRa) to mediate its transcriptional ef-
fects [22,202].
VDR is expressed in most tissues and regulates cellular differ-
entiation and function in many cell types. VDRs were initially
described in lymphocytes as far back as 1983 [201]. Since this
discovery, VDR has been described in a variety of immune cells
[258] for example macrophages [201], dendritic cells [4,34] as well
as B- and T-cells [95,155,156] such as CD4þ and CD8þ T-lympho-
cytes [258] and natural killer (NK) T-cells [5]. VDR is also present at
further locations relevant to asthma pathogenesis, including res-
piratory epithelial cells [91], fibroblasts [205,206] and in substantial
quantities in airway smooth muscle [15,35,36]. Upon VDR activa-
tion, the expression of multiple target genes is altered, which has
the potential to modify cellular processes for example inflamma-
tion and immune defense [151,220]. Once formed inside a cell/tis-
sue, 1,25D will be metabolized and degraded inside that cell/tissue.
Therefore, the presence of both 1a-hydroxylase and the VDR in
these specific locations suggests local effects of 1,25D in these cells/
tissues.
Despite recent advances in our understanding of vitamin D, its
deficiency is highly prevalence worldwide [104] with many po-
tential systematic effects. Recently, intense interest has focused on
the influence of vitamin D for respiratory diseases, particularly
asthma.
3.2. Potential mechanisms by which vitamin D may modulate
asthmatic disease
There are multiple potential mechanisms based on both in vitro
and in vivo research by which increasing vitamin D status may in-
fluence asthmatic disease. These mechanisms include: effects on
lung development, immunomodulation, airway smooth muscle
modulation, genetic effects, and altering the effect of anti-
asthmatic therapy. This section is intended to summarize the
existing mechanistic data regarding vitamin D and asthma
pathways.
3.2.1. Structural effects
Early investigations in 50 day old rats born to mothers deprived
of dietary vitamin D showed reduced lung compliance compared to
rats born to mothers whose diet was supplemented with vitamin D
[76]. Vitamin D regulated genes are found to be over-represented in
developing human and mouse lung transcriptomes [128]. This
finding suggests a significant association between early lung
development and asthma related phenotypes for vitamin D
pathway genes. Further, animal models have shown that VDD alters
lung structure and creates deficits in lung function [287]. The same
group used a community-based prospective birth cohort to show
that forced vital capacity Z-scores in human children of both sexes
at age 6 were positively associated with maternal 25(OH)D. This
effect was not apparent at 14 years of age, however maternal VDD
was positively associated with asthma at 6 years of age but only in
males only [288]. Indeed, children who were on inhaled
corticsteroids had poorer lung growth if they were VDD compared
to those that were not VDD [274].
Using an in vivo rat model, it was recently determined that VDD
was associated with increased airway resistance following meth-
acholine challenge and that this defect was blocked by vitamin D3
supplementation [280]. Therefore, it is plausible that transient and/
or consistent VDD in early life may lead to permanent susceptibility
to poorer respiratory outcomes, which may be independent of
atopy. Additional studies suggest that vitamin D is an important
regulator of lung growth in utero [68,188,189]. 1,25D has been
shown to suppress features of inflammation-induced airway
remodeling in fetal airway smooth muscle cells, suggesting the
importance of 1,25D in preventing and treating detrimental struc-
ture changes in developing lungs [35,36]. See also section 3.2.5 on
airway smooth muscle.
3.2.2. Anti-inflammatory effects
The broad spectrum anti-inflammatory effect of vitamin D on
various pathologies, including asthma, was recently reviewed
[271,277]. Briefly, Vitamin D has been shown to inhibit the pro-
duction of pro-inflammatory cytokines such as interleukin-6 (IL-6)
and tumor necrosis factor alpha (TNF-a) by monocytes via the in-
hibition of p38MAP kinase [285]. NF-kB is a ubiquitously expressed
transcription factor. Free NF-kB translocates to the nucleus where it
activates transcription of pro-inflammatory cytokines, anti-
apoptotic factors as well as of enzymes involved in the generation
of pro-inflammatory mediators such as COX-2 [125,247]. Activation
of VDR inhibits NF-kB activation and signaling. Further, it has been
shown that 1,25D down-regulates NF-kB levels in lymphocytes
[279].
Compared to control airway epithelial cells from adult asthmatic
during exacerbation, lipopolysaccharides (LPS) stimulated airway
epithelial cells demonstrated increased reactive oxygen species
(ROS), TNF-a, NFkB expression and phosphorylation as well as
increased DNA damage. However, the addition of 1,25D blunted
these effects significantly. Further, stimulation with hydrogen
peroxide (H2O2) induced ROS production and decreased glucocor-
ticoid receptor nuclear translocation as compared to untreated
cells. Pre-treatment with 1,25D significant blunted this in a dose-
dependent manner and enhanced the dexamethasone induced
glucocorticoid receptor nuclear translocation in H2O2 stimulated
cells [139].
3.2.3. Immunomodulation
Vitamin D has numerous effects on the immune system [56],
many of which are of relevance to the respiratory system [162]. For
example, vitamin D has potential to inhibit inflammation and in-
fections [151,263,276] by modulation of both the innate and
adaptive immune systems [60].
3.2.3.1. Innate immune. The addition of 1,25D to humanmonocytes
inhibits their expression of the toll-like receptors (TLRs) 2 and 4
leading to reduced production the pro-inflammatory cytokine TNF-
a [220,223]. In vitro studies have shown that 1,25D increases the
proliferation and maturation of monocytes into macrophages
[133,192]. Further studies have shown that VDD is associated with
defective macrophage function, including impaired chemotaxis,
phagocytosis and increased production of pro-inflammatory cyto-
kines [193,194].
Antimicrobial peptides (AMPs) are a group of highly diverse
micropeptides, which exert potent antimicrobial effects [74] and are
key modulators of lung inflammation and infection risk in asthma
[98]. Human cathelicidin antimicrobial peptide-18 (hCAP-18) is the
only known member of the cathelicidin family of antimicrobial
peptides that is expressed by humans [163]. LL-37 is a 37-residue
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active cationic peptide and is the cleavage product of cathelicidin
[237]. VDR activation by 1,25D regulates genes encoding for cath-
elicidin and other cationic peptides such as human defensin 2 and 4
by human cell lines [80,261], and multiple human cells including
monocytes/macrophages and epithelial cells [81,226,261,263] and
hence triggers their expression [80,150,151,261] at multiple sites
including the airways of healthy individuals [91,276] and cystic
fibrosis patients [276].
Additionally, the in vitro induction of hCAP-18 by 1,25D in
various human cells, including monocytes, neutrophils and respi-
ratory epithelial cells enhances antimicrobial activity against mul-
tiple respiratory pathogens including Mycobacterium tuberculosis,
Bordetella bronchiseptica and Pseudomonas aeruginosa
[151,163,261,276].
A cross sectional analysis 650 mostly black smokers revealed
that participants with low cathelicidin had significantly lower
forced expiratomy volume in 1 s compared to higher cathelicidin, a
relationship which remained after adjusting for confounders
(p ¼ 0.035). Although, 25(OH)D was associated with cathelicidin
levels, lung function decrements associated with low cathelicidin
were greatest among individuals with lower 25(OH)D levels [138].
25(OH)D did not correlate with serum LL-37 levels in healthy
individuals, but did correlate with the in vitro capacity to induce
monocyte hCAP-18 expression [2]. Further, a positive correlation
between serum 25(OH)D and cathelicidin levels has been noted
among healthy adults [24,62], subjects in intensive care [116], as
well as asthmatic children and adults [79]. Further, a significant
change in LL-37 levels was observed in subjects after vitamin D
supplementation, but only in those with the greatest increase in
serum 25(OH)D [24]. Liu et al. assessed 1,25D and ll-37 responses to
allergen exposure in bronchoalveolar lavage fluid (BALF) of allergic
human. Compared to saline control, exposure to allergen resulted
in significantly increased 1,25D (p ¼ 0.0006) as well as significantly
increased LL37 (p¼ 0.0005). Increases in 1,25D and LL37 correlated
with each other (P < 0.0001) and with inflammatory cellular
changes (p < 0.0001) [149]. These reports highlight a potential for
vitamin D to influence cathelicidin and related peptide and
potentially exert broad antimicrobial effects, which may have po-
tential to affect infection risk and hence susceptibility to asthma
exacerbation (see section 3.2.4).
3.2.3.2. Adaptive immune system. In contrast to its effect on the
innate immune system,1,25D seems to induce immunosuppressive
effects on the adaptive immune system through inhibition of IL-12
secretion [57], inhibition of lymphocyte proliferation and immu-
noglobulin synthesis [86] as well as impairment of dendritic cell
(DC) maturation, leading to the generation of tolerogenic DCs and
T-cell anergy [4].
3.2.3.3. B lymphocytes (B cells). 1,25D has multiple effects on B
cells, including inhibition of B cell proliferation, differentiation to
plasma cells, and production of immunoglobulins [51].
Healthy adults supplemented with oral vitamin D3 during the
winter months (2000e8,000 IU/d) for 12 weeks had increased
frequencies of circulating CD38 expressing B cells in peripheral
blood but not CD23 expressing B cells. This effect was confirmed
with in vitro experiments [66]. This is the first evidence that
vitamin D supplementation targets peripheral B lymphocytes.
3.2.3.4. T lymphocytes (T cells). T lymphocytes have a central reg-
ulatory role in the pathogenesis of asthma. It has been known since
1985 that 1,25D has potential to inhibit T cell cycle and proliferation
[212]. 1,25D directly targets T lymphocytes [257] and can act
directly on T cells inhibiting the development and function of
multiple T-helper (Th) cells including Th1, Th9 and Th17 cells while
favoring the development of regulatory T-cells [122,243].
The role of vitamin D on Th2 cells is not consistent. Some have
suggested a direct signaling effect of vitamin D on naive CD4þ T
cells toward Th2 differentiation or maintenance [135,165]. Indeed,
murine evidence suggests that vitamin D shifts the Th1eTh2
cytokine balance toward Th2 [27,135,142,165,166,169,193,194]; and
thus potentially increases risk of asthma [264] and allergy [165].
However a recent animal model study demonstrated that peri-
natal VDD in mice resulted in Th2 skewing and reduced IL-10-
secreting regulatory T cells. These effects were augmented by
exposure to house dust mite. In contrast, vitamin D supplementa-
tion was associated with significantly reduced serum IgE levels,
pulmonary eosinophilia and peri-bronchiolar collagen deposition
[253]. These contradictory reports regarding the effects of 1,25D on
Th2 responses are based mostly on animal or in-vitro models
[118,140,165]. In vitro work with human cord blood cells has
demonstrated inhibition of both Th1 and Th2 differentiation with
1,25D [198], whereas 1,25 decreased Th1 cytokines and increased
Th2 cytokines in stimulated peripheral blood mononuclear cells
(PBMCs) from subjects with inflammatory bowel disease [12].
The inconsistences regarding the effect of vitamin D on Th2
responses probably reflect varying protocols and differing doses of
1,25D, which may potentially explain the observation that both
high and low 25(OH)OD levels have been associated with increased
aeroallergen sensitization [216], elevated IgE levels [109], and
adverse changes in lung function [245], raising the possibility that
an optimal level of 25(OH)D exists regarding asthma and that levels
above or below may be detrimental. However in this context, it is
noteworthy that existing reports suggest that increasing 25(OH)D
did not enhance Th2 cytokine levels in human peripheral blood
[155,156,251].
3.2.3.5. T-helper cells. Asthma is considered mainly as a Th2
mediated disease, characterized by production of IL-4, IL-5, and IL-
13 together with eosinophilic infiltration of the bronchial mucosa.
However, a CD4þ Th17 mediated response has also been observed
in asthmatics with chronic inflammation [8,171,195].
At the molecular level, 1,25D has been shown to be involved in
the suppression of DC maturation and consecutive Th1 cell devel-
opment [11,19,174]. In fact, vitamin D may suppress the production
of IL-12, thereby reducing the production of Th1 cells and poten-
tially leading to increased proliferation of allergy-associated Th2
cells [19,118]. Additionally, studies in mice have shown that treat-
ment with 1,25D results in reduced secretion of the Th1 cytokines
IL-2 and interferon gamma (IFN-g) and an increase in Th2 type IL-4
[165].
CD4þ T cells, and associated Th2 cytokines are thought to have a
pivotal role in the recruitment and activation of the effector cells of
the allergic response [146]. It has been known since the late 1980s
that 1,25D has modulatory effects regarding the function of CD4þ T
cells [257].
Healthy adults supplemented with oral vitamin D3 during the
winter months (2000e8,000 IU/day) for 12 weeks had no effect on
T cell subsets. However, in stimulated CD4þ T helper cells there
were significant decreases of both IFN-g producing T cells and IL-17
producing T-17 cells in the vitamin D group compared to the control
group (both p < 0.001) [66]. Th9 cells are important in the asthma
pathogenesis. In vivowork has demonstrated 1,25D is additive with
dexamethasone in decreasing inflammatory cytokine production
from Th-9 subsets, which are implicated in asthma [126].
Th17 cells constitute a subset of effector T helper cells func-
tioning distinctly from other T helper cells. The pro-inflammatory
role of Th17 cells and Th17 associated cytokines (IL-17A and IL-
17F) is widely recognized [55]. There is an increased number of
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Th17 cells in both blood and induced sputum in childhood asth-
matics compared to non-asthmatics [90]. Chang et al. [47] observed
a dose dependent reduction in IL-17A productionwhen naive CD4þ
Tcells were culturedwith transforming growth factor alpha (TGFa),
IL-6 and increasing concentrations of 1,25D. A recent in vitro study
demonstrated that stimulation of naive CD4þT cells under Th17
polarizing conditions in asthmatics showed a higher Th17 cell dif-
ferentiation than healthy controls. The addition of 25(OH)D
significantly inhibited Th17 cell differentiation dose-dependently,
both from asthmatic (p < 0.001) and non-asthmatic children
(p ¼ 0.001). Further, 25(OH)D inhibited RORC, IL-17, IL-23R, and
CCR6 gene. Additionally, treating DCs from asthmatics with 25(OH)
D significantly inhibited IL-17 production (p ¼ 0.002) and
decreased the percentage of CD4(þ)IL-17(þ) (p ¼ 0.007). Overall,
these findings suggest that vitamin D3 has an inhibitory effect on
Th17 responses and this response is mediated via both T cells and
DCs [289].
3.2.3.6. Gamma delta T cells (gd T cells). gd T cells represent a small
number of T cells, which appear important in allergic airway
inflammation. gd T cells have been reported to be decreased in the
blood of asthmatics compared to controls [49,130,239]. Decreased
peripheral gd T cell populations are thought to be due to their
enhanced capacity to migrate from peripheral blood through the
endothelium to the inflamed airways [14,239]. Moreover, gd T cells
have been demonstrated to be increased in the BALF of patients
with allergic asthma and 1,25D has been found to significantly
inhibit the proinflammatory activity of gd T cells in a dose-
dependent fashion [50].
3.2.3.7. Regulatory T-cell (T-regs). T-regs inhibit (effector/antigen
specific) T cells by several inhibitory mechanisms to suppress
overzealous immune responses and regulate immune responses
[48,227,259]. Current evidence suggests that many of these inhib-
itory pathways are mediated through altered IL-10 and TGF-b
production. Reduced T-reg number and function has been linked
with glucocorticosteroid resistance [61,213]. VDD has been associ-
ated with reduced T-reg number and function both directly and
indirectly through antigen presenting cells [46,61,92].
25(OHOD levels correlated with T-reg number and function in
patients with multiple sclerosis [217,234,235]. In asthmatic human
airway lymphocytes, Foxp3(þ) and IL-10(þ) T-reg numbers were
correlated with 25(OH)D levels [250]. T-regs from steroid resistant
(SR) asthmatics have been found to secrete less of the anti-
inflammatory cytokine IL-10 in response to dexamethasone.
However, culturing such T-regs in the presence of both dexa-
methasone and 1,25D seems to reverse this defect [275]. Further,
1,25D has been shown to increase the production of T-regs
[46,84,85,251,275] and T-reg function [47,115,179], which may
prove to be an additional mechanism for its immunomodulatory
role.
3.2.3.8. Forkhead box P3 (FoxP3). FoxP3 is a transcription factor and
is specifically expressed by CD4þCD25þ T-regs. FoxP3 controls
CD4þCD25þ T-reg development and function [207]. 1,25D en-
hances the frequency of human Foxp3þ T-reg cells in vitro and
directly enhances the production of T-regs from CD4þFoxP3þ T-
regs [115]. 1,25D has been shown to promote a tolerogenic
phenotype in human DCs, leading to the induction of FoxP3 T-regs
[196]. Further, 25(OH)D levels have been found to correlate posi-
tively with CD4(þ)FoxP3(þ) T-cell numbers in moderate/severe
asthmatics [44]. The effect of 1,25 on FoxP3 (þ) T-reg cells seems to
be magnified in the presence of certain cytokines, particularly TGF-
b [45].
3.2.3.9. Interleukins. Interleukins are a subtype of cytokine that are
secreted by white blood cells (WBCs). Many interleukins are rele-
vant in asthma but we will limit our discussion to two main in-
terleukins which can be influenced by vitamin D:
3.2.3.9.1. Interleukin-10 (IL-10). IL-10, which is produced by
monocytes and to a lesser extent lymphocytes, including T-regs, is
an anti-inflammatory and immunosuppressive cytokine. Its anti-
inflammatory mechanisms include inhibition of antigen present-
ing cell function [176], inhibition of cytokine production by mac-
rophages and DC [176], inhibiting T-cell, mast cell and eosinophil
activation as well as inhibition of pro-inflammatory cytokine pro-
duction [93,191]. This combination leads to profound inhibition of
Th1 cell-mediated immunity [176].
Several studies have noted an inverse relationship between IL-
10 levels and asthma severity [28,147]. In addition, alveolar mac-
rophages from asthmatic subjects secrete lower IL-10 levels than
non-asthmatic subjects [28,119,147]. Hence, it is widely believed
that IL-10 has an important role in controlling the magnitude of
human immune responses and in controlling airway inflammation.
Active vitamin D response elements have been identified in the
IL-10 gene [96,167,168]. Cord blood 25(OH)D has been inversely
associated with IL-10 concentration [286]. 1,25D administration has
been associated with increased IL-10 gene expression in
CD3þCD4þT cells from steroid refractory asthmatics [251]. Addi-
tionally, 1,25D has also been reported to increase IL-10 secretion
from B cells in vitro [96]. Further, 1,25D has been demonstrated to
potentiate the beneficial effects of allergen immunotherapy in an
animal model of asthma through modulating of IL-10 and TGF-b
[242]. Human in vitro evidence suggests that vitamin D supple-
mentation could potentially increase the therapeutic response to
glucocorticoids by restoring the impaired steroid-induced IL-10
response [275]. Clinical support was provided by a double-blind,
randomized, placebo controlled trial (DBRCT) in heart failure
patients demonstrating that daily supplementation with 2,000 IU
vitamin D3/day for 9 months increased plasma IL-10 [224].
Together these data suggest that sufficient 25(OH)D levels may be
associated with increased IL-10 expression and/or function, which
seems important for asthma control.
3.2.3.9.2. Interleukin 33. IL-33 is a cytokine that acts onmultiple
cells, including Th2 lymphocytes, to promote Th2 cytokine secre-
tion and airway inflammation [75,146]. The genes IL33 and inter-
leukin 1 receptor-like 1 (IL1RL1) have been identified as
predisposing to asthma risk [87]. A 2014 in vitro study assessed IL-
33 and IL1RL1 expression from human bronchial epithelial cells
(HBECs), CD4 lymphocytes, CD8 lymphocytes, eosinophils, and
mast cells when cultured in the presence or absence of 1,25D.
Addition of 1,25D significantly increased expression of the gene
hCAP as well as the total number of IL1RL1 mRNA transcripts
expressed by HBECs and CD4 and CD8 lymphocytes but not in
primary eosinophils or mast cells. Further, HBECs cultured with
100 nmol/L 25(OH)D resulted in increased expression of both
IL1RL1 and the soluble decoy receptor for IL-33 sST2 (which in-
hibits the actions of IL-33). The authors suggest that ‘the capacity of
vitamin D to augment the synthesis of an inhibitor of IL-33… is of
potential benefit in the limitation of asthmatic mucosal inflam-
mation’ [197]. Clinical support comes from a 2014 human study
demonstrated higher 25(OH)D in healthy controls compared to
subjects with allergic rhinitis (AR) or asthma þ allergic rhinitis
(AAR), while plasma IL-31 and IL-33 were lower in subjects with AR
or AAR. However, there was no correlation between 25(OHOD and
either IL-31 or IL-33 [26].
3.2.4. Decreasing infection risk and/or severity
Early life respiratory tract infections (RTIs) have been associated
with increased risk of asthma development [18,107,112]. Although
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there is no evidence that asthmatics are more prone to RTIs than
non-asthmatics, RTIs are a powerful trigger of asthma exacerba-
tions [41,159] and typically lead to more severe symptoms
compared to non-asthmatics [53,65]. Any intervention, which
could decrease the susceptibility to either bacterial or viral RTIs,
could potentially significantly decrease the frequency of asthma
exacerbations and flairs.
Considering the immunomodulatory effects of 1,25D, it is
plausible the vitamin D status could alter susceptibility and effects
of RTIs [43] and it has been suggested that vitamin Dmay represent
an important link between RTIs and asthma [77,78]. The association
between RTIs and vitamin D can be seen with several studies
associating rickets (classical vitamin D deficiency) with increased
risk of RTIs [180,183,210] and wheezing [70]. In Hawaiian children
(<5y), viral bronchiolitis, respiratory syncytial virus (RSV), and
pneumonia vary with both season and skin pigmentation [82]
suggesting a role for vitamin D. Additionally, single nucleotide
polymorphisms in four of the innate immunity genes, including the
VDR, seem to increase susceptibility to RSV bronchiolitis [113,131]
and general lower RTI [215].
Vitamin D has potent bactericidal effects [101] and virucidal
effects [157,249]. However, 1,25D appears to have little effect on
virus replication in airway epithelial cells. Rather the anti-infective
properties of 1,25D appear related to potentiation of CXCL8 and
CXCL10 secretion from both infected or uninfected cells and alter-
ation of cell morphology, including thickening of the cell layers
(p < 0.01) and proliferation of cytokeratin-5-expressing cells.
Indeed, any potential anti-viral effect of vitamin D appears due to
altered growth and differentiation of airway epithelial cells as
opposed to direct effects on viral load [37].
Recent observational studies have reported that low 25(OH)D is
associated with increased incidence [77,78,124,137,219]; and
severity of RTIs [143,172,262]. One study suggested that a serum
level of 25(OH)D 95 nmol/L was associated with decreased RTI
incidence compared to lower levels [219]. A detailed retrospective
analysis from the UK, demonstrated a seasonal pattern of infection,
which closely mirrored 25(OH)D levels [21]. Indeed, solar UV-B
radiation exposure (a proxy for vitamin D) has been inversely
associated with diverse respiratory tract symptoms [244], RSV
incidence [265,281] and risk of invasive pneumococcal disease
[267]. However, subsequent vitamin D supplementation DBRCTs
have yielded conflicting results, with some reporting decreased risk
[10,13,42,136,249,252], some reporting decreased duration [161]
but others still reporting no difference [145,160,181].
These observed discrepancies may be partly be accounted for by
differences in vitamin D dosing, interventional period, definition of
RTI as well as baseline and endpoint 25(OH)D levels. Further, the
protective effect of vitamin D against RTIs may be specific to high-
risk populations, such as wheezing children [114] or those with
asthma [32,77,78,157,249,252]. Indeed, two small intervention tri-
als of vitamin D supplementation in pediatric asthma have
demonstrated decreased RTI risk and hence decreased asthma ex-
acerbations [157,249]. Therefore, increasing vitamin D as a RTI
prevention strategy, particularly in asthmatics, warrants further
investigation.
3.2.5. Airway smooth muscle
Airway smooth muscle (ASM) cells play a central role in asth-
matic disease. ASM cells modulate bronchomotor tone in the
airway lumen and airway resistance is primarily influenced by
airway diameter. Therefore, small changes in airway radius can
greatly influence airflow. Increased ASM hypertrophy and hyper-
plasia have been demonstrated in endobronchial biopsies from
children with severe asthma and are significantly related to bron-
chodilator responsiveness [209]. Further, phenotypic changes to
ASM, mediated by pro-inflammatory cytokines, are important for
the airway remodeling process [63].
To date, there is little evidence that standard asthma therapies
affect airway remodeling. However, vitamin D is a potential mod-
ifier of this process. Not only do ASM cells possess the enzymatic
machinery to form 1,25D from 25(OH)D [15,30] and contain the
VDR [15], but 1,25 modulates the synthetic activity of ASM cells and
decreases expression of inflammatory chemokines. Treating ASM
cells with TNF-a and/or IFN-gmimics the inflammation of an acute
asthmatic flare and facilitates the in vitro examination of the effi-
cacy of potential anti-inflammatory therapies. TNF-a and/or IFN-g
treated ASM cells exposed to 1,25D had a dose-dependent decrease
in inflammatory cytokine production [15]. In addition, both
RANTES (a pro-inflammatory molecule that attracts monocytes,
eosinophils, and T-cells) and IP-10 (a pro-inflammatory mediator
that recruits activated Tcells, NK cells, andmast cells) were noted to
be significantly decreased with 1,25D treatment [15].
A potentially important effect of vitamin D on asthma is a strong,
direct anti-inflammatory effect in ASM, evident from the suppres-
sion of both bronchial ASM proliferation, as well as mucus and
matrix metalloproteinase secretion by cultured human bronchial
cells [6,236], potentially because 1,25D downregulates the
expression of MMP9 and ADAM33 (both known modulators of
airway remodeling). Vitamin D treatment also increases ASM cell
VDRs and at physiologic concentrations partially prevents ASM
cells from becoming passively sensitized by exposure to asthmatic
serum [236]. Further in vitro studies have demonstrated that 1,25D
has a direct inhibitory effect on both passively sensitized ASM cells
[236] as well as the growth of human ASM cells (both asthmatic
and non-asthmatic)via growth factor-induced phosphorylation of
retinoblastoma protein and checkpoint kinase 1 [58]. Clinical evi-
dence was observed by Gupta et al. who, using endobronchial bi-
opsies, demonstrated that 25(OH)D levels were inversely related to
ASM mass in children with severe asthma [89].
In vitro, 1,25D has been demonstrated to attenuate the pro-
inflammatory and pro-fibrotic effects of pro-inflammatory cyto-
kines (TNFa and TGF-b) in terms of extracellular matrix formation
and cell proliferation in human fetal ASM and to suppress features
of inflammation-induced airway remodeling in fetal ASM cells
[35,36]. A recent study demonstrated that when human bronchial
epithelial cells were stimulated with TGF-b1 or TGF-b2 cell motility
was increased. However, the addition of 1,25D appeared to inhibit
both migration and invasion induced by TGF-b1 and TGF-b2 [73].
Tissue repair and remodeling, a key feature of asthma, is
partially mediated through fibroblasts which modulate tissue
repair by producing and modifying extracellular matrix compo-
nents and by releasing mediators that act as autocrine or paracrine
modulators of tissue remodeling. Vitamin D, 25(OH)D and 1,25D all
significantly reduced prostaglandin E2 (PGE2) production by hu-
man lung fibroblasts and stimulated an enzyme responsible for
prostaglandin E2 degradation [152]. These findings suggest that
vitamin D can regulate PGE2 synthesis and degradation which can
modulate fibroblast-mediated tissue repair function. Further,
fibroblast proliferation upon treatment with TGF-b1 (an important
driver of many fibrotic disorders, including asthma) was inhibited
by 1,25D in a dose-dependent fashion. Similarly, TGF-b1-induced
upregulation of mesenchymal cell markers and abnormal expres-
sion of epithelial cell markers were blunted by 1,25D [205,206].
These observations suggest that under TGF-b1 stimulation, 1,25(D
inhibits the pro-fibrotic phenotype of lung fibroblasts and epithe-
lial cells.
Taken together, these findings suggest 1,25D may be a novel,
important agent for the prevention and treatment of detrimental
structure changes in the airways. The link between vitamin D and
airway remodeling has recently been reviewed [20].
C.P. Kerley et al. / Pulmonary Pharmacology & Therapeutics 32 (2015) 60e74 65
Author's personal copy
3.2.6. Vitamin D as an adjunct to anti-inflammatory therapy in
asthma
Twomajor pharmacological treatments for asthma currently are
glucocorticoids and immunotherapy. The anti-inflammatory and
immunomodulatory effects of vitamin D, suggest potential to
improve the efficiency of these anti-inflammatory therapies.
3.2.6.1. Immunotherapy. Allergen-specific immunotherapy is a
unique form of therapy capable of changing the course of disease in
allergen-sensitive rhinitis and asthma. This form of treatment in-
creases allergen-specific immunoglobulin G (IgG) 1 and 4, induces
T-regs and thereby peripheral tolerance leading to clinical
improvement [1,7].
In murine models, pretreatment with 1,25D has the capacity to
enhance the inhibitory effects of immunotherapy on allergic airway
inflammation [97,153,242,255]. These preliminary results preceded
human intervention work, whereby pre-treatment or adjuvant
therapy with vitamin D, improved the efficiency of immunotherapy
[16,157,158] e see section 3.1.6 in part two of this review [127].
3.2.6.2. Glucocorticoids. Glucocorticoids (GCS) are the first line
anti-inflammatory treatment for asthma and are the most effective
anti-inflammatory treatment currently available [248]. Their mul-
tiple inhibitory properties include inhibition of Th2 cytokine syn-
thesis and enhanced IL-10 production by stimulated T cells [211]
and airway cells [119]. Most patients with asthma respond to
standard therapy with inhaled bronchodilators and GCS. However,
approximately 15% of asthmatics fail to benefit from GCS. This is
termed steroid resistant (SR) asthma [54]. SR asthma is associated
with in vitro and in vivo alterations in cellular responses to exoge-
nous GCS, including decreased IL-10 secretion by CD4þ T cells [92].
Despite the use of multiple high dose medications, individuals with
SR asthma experience frequent exacerbations [266] and contribute
excessively to the asthma-related morbidity and mortality [218]. In
addition to SR asthma, GCS side effects e which have been shown
to be strictly dose-dependent [214] e frequently limit long term
GCS application. Therefore, it is desirable to lower the dose of GCS
treatment while maintaining the anti-inflammatory effect.
3.2.6.2.1. Vitamin D status is associated with steroid response.
An inverse association between 25(OH)D and the use anti-
inflammatory medication (either inhaled corticosteroids or leuko-
triene inhibitors) has been noted in asthmatic children in Costa Rica
[32] and America [228]. Conversely, vitamin D insufficiency (VDI)
may lead to down-regulation of GCS pathways and thus a greater
need for steroids, particularly in children. For example, there was
an association between lower 25(OH)D and decreased in vitro ste-
roid response in a small cohort (n ¼ 54) of mild-moderate adult
asthmatics [241]. However, GCS requirements and in vitro steroid
responsiveness were significantly inversely associated with 25(OH)
D level in childhood asthmatics. While trends for association were
also seen for adult asthmatics, these did not reach statistical sig-
nificance, suggesting a stronger that effect in childhood asthmatics
[79]. Although the sample size was small (50 adult asthmatics and
53 childhood asthmatics), this study was the first to compare
corticosteroid responsiveness and vitamin D status between chil-
dren and adults. Further, it has been shown in vitro [275] and in vivo
[184,275]. that co-administration of 1,25Dwith GCS couldmodestly
improve GCS responsiveness in SR asthma.
3.2.6.2.2. Vitamin D may attenuate steroid resistance and work
synergistically with steroids. An early report of the effect of
dexamethasone þ differing concentrations of 1,25D on PBMCs,
demonstrated that 1,25D could act synergistically with dexa-
methasone to decrease Th1 cytokines (IFN g) but increase Th2 cy-
tokines (IL-5, IL-13) compared to dexamethasone alone [118].
T-regs from SR asthmatics have been found to secrete less of the
anti-inflammatory cytokine IL-10 in response to dexamethasone. A
subsequent in vitro investigation with CD4þ T cells from patients
with SR asthma showed that the addition of 1,25D could potentially
increase the therapeutic response to GCS by restoring the impaired
steroid-induced IL-10 response [275]. Interestingly, they showed
that oral administration of vitamin D3 reversed steroid resistance in
3 adult asthmatics through induction of IL-10-secreting T-regs.
1,25D. Further, it is known that corticosteroids modulate ASM
chemokine secretion in vitro. However, co-administration of both
1,25D and corticosteroids resulted in additive inhibition of che-
mokine secretion suggesting a synergistic relationship [15].
In a randomized trial of inhaled budesonide versus nedocromil
versus placebo, VDI was associated with increased risk for severe
asthma exacerbations leading to emergency department visits or
hospitalizations. In this study, the group with the lowest risk for
exacerbations was the group who had 25(OH)D levels >75 nmol/L
and whowere on inhaled corticosteroids (ICS), further suggesting a
synergistic effect between vitamin D status and corticosteroids
[33].
Increased expression of mitogen-activated protein kinase 1
(MKP-1), a protein involved in directing cellular responses to a
diverse array of stimuli, leads to more effective corticosteroid
induced anti-inflammatory and immunosuppressive effects. MKP-1
expression can be used as a marker of responsiveness to GCS.
Another mechanism of GCS resistance involves the ability to
regulate inflammatory gene expression and GCS receptors. In vitro,
physiologic concentrations of 1,25D added to dexamethasone
significantly enhanced MKP-1 expression in PBMCs compared with
dexamethasone alone, suggesting that the addition of vitamin D
could decrease the dexamethasone dose requirement bymore than
10-fold. Interestingly, this relationship was stronger in patients
who were steroid naıve [228].
Corticosteroid-exposed airway cells and PBMCs from asthmatics
treated with 1,25D exhibited enhanced induction of MKP-1 and IL-
10. Further, increased 25(OH)D levels were associated with
improved lung function in vivo and with improved corticosteroid
responsiveness in vitro [228]. The inability to trigger production of
MKP-1 is one of the known mechanisms of SR, which is interesting
because MKP-1 is considered a vitamin D target gene [285]. Indeed,
it has been demonstrated that MKP-1 levels increase in parallel
with 25(OH)D levels suggesting that vitamin D may improve GCS
response [241].
Both 25(OH)D and 1,25D dose dependently inhibited LPS-
induced p38 phosphorylation at physiologic concentrations as
well as IL-6 and TNF-a production by human monocytes. MKP-1
expression was significantly upregulated in human monocytes
and increased binding of the VDR was observed [285]. 1,25D
stimulated GCS induction of MKP-1 and enhanced GCS inhibition of
LPS-induced IL-6 signaling enhanced GCS responses in human
PBMCs [284]. PBMCs from 11 SR asthmatics and 8 steroid sensitive
(SS) asthmatics were pre-incubated with 1,25 D followed by
dexamethasone treatment and LPS stimulation. Dexamethasone
significantly inhibited LPS-induced phosphorylated p38 mitogen-
activated protein kinase in monocytes from patients with SS
asthma but not those from patients with SR asthmatics (p < 0.01).
However, 1,25D inhibited LPS-induced phosphorylated p38
mitogen-activated protein kinase in monocytes from both patient
groups (p < 0.01). Further, 1,25D enhanced dexamethasone sup-
pression of LPS-induced phosphorylated p38 mitogen-activated
protein kinase in monocytes, but only from patients with SS
asthma (p < 0.01). 1,25D induced MKP-1 expression and enhanced
dexamethasone induction of MKP-1 in SS asthmatics and SR asth-
matics. However, the responses to GCS in SR asthmatics remained
significantly lower than those with SS asthma (p < 0.05).
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VitaminDandcorticosteroids synergistically induce a tolerogenic
DC phenotype [72] that may be important for immunomodulation
and decreased responsiveness to self and external antigens (e.g. al-
lergens). This study investigated differential protein pathways in
human CD14þ monocytes that were differentiated toward mature
DCs, in the presence or absence of vitamin D and/or dexamethasone.
VitaminDwasmorepotent thandexamethasone in skewing thecells
from the pro-inflammatory phenotype seen in the untreated DCs.
Both dexamethasone and 1,25D have the ability to inhibit pro-
duction of pro-inflammatory cytokines (e.g. TNF, IL-6) from LPS
stimulated PBMCs in cell culture. However, when administered
concurrently the effects were additive. The mechanism was shown
to involve stimulation of dexamathasone induction of MKP-1.
Granulocyte macrophage colony-stimulating factor (GM-CSF) was
shown to mediate the enhancement of dexamethasone-induced
MKP-1 production in monocytes via increased production of
mediator complex subunit 14 [284].
An in vitro study of PBMCs from SR asthmatics, SS asthmatics
and healthy controls demonstrated that asthmatics produced
higher levels of Th17-associated cytokines (IL-17A and IL-22).
Stimulation of PBMCs with dexamethasone did not inhibit IL-17A
cytokine expression. However, treatment of PBMCs with 1,25D,
both in the presence and absence of dexamethasone significantly
reduced both IL-17A and IL-22 levels. The inhibitory effect of 1,25D
was evident in all patients studied, irrespective of their clinical
responsiveness to steroids identifying novel steroid-enhancing
properties of vitamin D in asthmatic patients [185]. In vivo work
has demonstrated that 1,25D is additive with dexamethasone in
decreasing inflammatory cytokine production from T-cell subsets
implicated in asthma [126].
A recent animal study lends support to these in vitro studies.
Monotherapy with vitamin D or dexamethasone attenuated the
increased WBC count, serum IgE, nitric oxide and IL-5 levels
observed among rats with ovalbumin-induced airway inflamma-
tion. However, combination therapy with vitamin D þ dexameth-
asone was shown to be superior to either alone [173].
Several human studies have suggested a beneficial synergistic
effect between vitamin D and GCS in asthma outcomes
[33,79,157,228,274]. Possible mechanisms whereby vitamin D may
mediate increased steroid responsiveness include inhibition of
fractalkine secretion [15] and increased T-reg production and
function (reviewed above) as well as increased GCS bioavailability
in ASM cells induced by 1,25D [30].
Vitamin D supplementation may potentiate the anti-
inflammatory function of corticosteroids in asthmatic patients.
The evidence that vitamin D has additive effects on the adminis-
tration of corticosteroids is reviewed fully elsewhere [148].
3.2.6.2.3. Vitamin D may prevent the adverse effects of anti-
inflammatory therapies in asthma. Majak et al. conducted a
double-blind, placebo controlled trial to assess specific immuno-
therapy (SIT) in combination with ICS (prednisone 20 mg daily) þ
either placebo or vitamin D3 (1000 IU/week) [158]. Early adminis-
tration of ICS prevented the benefits of SIT. However, the addition of
low dose vitamin D (143 IU/day) preserved the benefits of SIT,
despite concomitant ICS use. Indeed, all negative clinical- and
immunological-effects of prednisone were prevented by the
administration of vitamin D3.
Children who were on ICS had poorer lung growth if they were
VDD compared to those that were not VDD [274]. According to
cross-sectional data from National Health and Nutrition examina-
tion survey (2001e2006), GCS users seem to be at higher risk of
VDD (OR, 2.36; 95% CI, 1.25e4.45) compared to non-users. It was
concluded that GCS use is independently associated with VDD, and
the need for screening patients with chronic steroids usage was
suggested [233].
These human studies are supported by a recent animal study.
Dexamethasone-induced hyperglycemia, hyperlipidemia, and
behavioral abnormalities in allergic rats but these effects were
attenuated with vitamin D co-administration [173]. These studies
suggest that optimizing vitamin 25(OH)D levels may be of impor-
tance in increasing the effectiveness of anti-inflammatory therapies
and decreasing potential side-effects.
3.2.7. Interplay of the genome and vitamin D status to influence
asthma
It is recognized that asthma may develop as a consequence of a
variety of gene-environment interactions. Vitamin D synthesis,
transport and degradation are controlled by several genes, partic-
ularly genes encoding for the vitamin D binding protein (VDBP) and
the vitamin D receptor (VDR). Polymorphisms in these genes may
affect both 25(OH)D status and the effects of 1,25D. For example,
human genome-wide linkage evaluation has shown strong genetic
regulation of serum 25(OH)D levels, but not 1,25D levels [268].
3.2.7.1. Vitamin D receptor (VDR). The biological effects of 1,25D are
mediated via the VDR [182]. VDR polymorphisms have been
significantly associated with asthma in studies of Chinese [218],
American [200,203], AfricaneAmerican [199] and Tunisian [154]
populations. However, further studies have failed to confirm this
association among Chinese [71] and German [260,270]) pop-
ulations. Indeed, a large cross sectional study in the UK found that
25(OH)D was not related to forced expiratory volume in 1 s and
VDR genotypes were unrelated to lung function and did not modify
the effects of dietary vitamin D intake or 25(OH)D concentrations
on lung function [230]. However, a recent meta-analysis of case-
control studies demonstrated that FokI polymorphisms were
marginally associated with asthma risk (OR 1.187; p ¼ 0.088) and
that both TaqI polymorphisms (OR 1.488, p ¼ 0.040) and BsmI k
polymorphisms (OR 2.017; p ¼ 0.017) were significantly associated
with asthma [246]. Gender and age modified the association of
these single nuclear polymorphisms (SNPs) with asthma, poten-
tially explaining some of the discrepancies displayed from exiting
observational and interventional research e see part two of this
review [127].
A 2014 Greek study assessed, for the first time, potential asso-
ciations between VDR polymorphisms (FokI, BsmI, ApaI, and TaqI)
and asthma control as assessed with Global Initiative for Asthma
score and Asthma Control Test (ACT) score. Although, there was no
association between VDR polymorphisms and asthma prevalence,
asthmatic children with the VDR ApaI-aa genotype had signifi-
cantly higher ACT scores compared with asthmatic children car-
rying the Apal aa/ac genotypes (p ¼ 0.011). The frequency of VDR
ApaI-aa genotype was significantly higher in controlled asthmatics
(n ¼ 92) compared to uncontrolled asthmatics (p ¼ 0.001). Further,
VDR ApaI-aa genotype was negatively associated with limitation in
daily activities because of asthma (p ¼ 0.004) but positively asso-
ciated with well-controlled asthma [110]. This study has provided
the first evidence that VDR SNPs may modulate both asthma con-
trol and response to vitamin D in asthma.
3.2.7.2. Vitamin D binding protein (VDBP). VDBP is a serum protein
that binds the majority of circulating 25(OH)D and 1,25D with high
affinity [238]. Bioavailable vitamin D is that 25(OH)D which is not
bound to VDBP. VDBP possesses independent immunomodulatory
functions, which predominantly relate to macrophage activation
and neutrophil chemotaxis [52]. These immunomodulatory func-
tions appear of particular relevance to RTIs [208] and inflammation
[25,272]. VDBP variants have been associated with asthma sus-
ceptibility in a Chinese population [144]. Additionally, a recent
study of 463 Hispanic children at 6 and 36 months of age
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demonstrated that a specific genotype of VDBP might confer pro-
tection against the development of asthma [186].
Compared to non-asthmatic controls and moderate asthmatic
children, children with SR asthma had significantly higher levels of
VDBP in BALF but not in serum. Further, VDBP concentration in
BALF correlated negatively with asthma control and percentage of
predicted forced expiratory volume in 1 s but positively with ICS
usage [88]. A recent study analysed the regulation of factors of the
vitamin D axis during the early and late-phase reaction of asthma in
15 patients. A significant increase in VDBP and 25(OH)D3 but not
1,25D in the BALF from mild asthmatics 24 h after allergen chal-
lenge was noted [31].
Specific VDBP- and VDR SNPs were significantly associated with
pediatric asthma development in a case-control study among
Egyptian children [111]. Other studies have associated non-VDR
genetic variation to paediatric asthma [269], including 25-
hydroxyalse [199]. There is evidence that SNPs in genes encoding
for 25-hydroxylase can directly affect presence of asthma, and SNPs
in the VDR gene can affect asthma morbidity and lung function, as
well as number of positive allergen tests and IgE elevation [199].
3.2.7.2.1. Additional studies of vitamin D genetics relevant to
asthma. A genome wide association analysis provided mixed con-
clusions regarding vitamin D-asthma genetics [141]. However, a
subsequent genome-wide study of geneevitamin D interactions in
asthma exacerbations identified 3 common variants in the class I
MHCerestricted T celleassociated molecule gene (CRTAM) that
were associated with an increased rate of asthma exacerbations
based on the presence of low 25(OH)D. These findings suggest an
important gene-environment interactionwhereby vitamin D status
can influence CD8þ and NK T cells, as well as asthma exacerbation
[67]. A 2013 study observed that vitamin D regulated genes were
markedly over-represented in normal human and mouse devel-
oping lung transcriptomes [128]. This finding suggests a significant
association between early lung development and asthma related
phenotypes for vitamin D pathway genes, supporting a genomic
mechanistic basis for the epidemiologic observations relating
maternal and neonatal vitamin D intake/25(OH)D and childhood
asthma susceptibility [175,204].
When human bronchial ASM cells were stimulated with 1,25D
over 400 genes e including genes implicated in asthma were
regulated [30]. The same research group went on to demonstrate
modest associations of asthmawithmultiple genes in the vitamin D
metabolism pathway, and multiple genes regulated by 1,25D [29].
Further, a recent DBRCT of low (400 IU/d) vs. high (2,000 IU/d) dose
vitamin D3 supplementation for 8 weeks demonstrated that
improved 25(OH)D status was associated with at least a 1.5 fold
alteration in the expression of 291 genes involved in expression of
WBCs [291], which may be of relevance to asthma. A recent
microarray analysis of adult non-smokers revealed that the
expression of thirteen candidate genes from small airway epithelial
cells were significantly altered by serum 25(OH)D (p < 0.05), and a
genome-wide significant expression quantitative trait loci associ-
ationwas detected for sphingosine-1-phosphate phosphatase 2e a
gene associated with lung function [294]. Similarly to children,
these finding suggests a significant association between lung
function, immune homeostasis and vitamin D pathway genes,
supporting a genomic mechanistic basis for the epidemiologic ob-
servations relating intake/25(OH)D and adult asthma susceptibility.
These interesting observations suggest a role for VDR, VDBP and
potentially other genes as well 25(OH)D in asthma pathogenesis.
The apparent discrepancies in vitamin D-asthma-genetic studies
may be due to differences in phenotypes related to age or asthma
duration and/or sample size issues. Nevertheless, the preponder-
ance of currently available data suggest that genetic abnormalities
may be an additional pathway by which inadequate 25(OH)D levels
are linked with asthma pathogenesis and severity.
3.2.8. Additional health benefits for the asthmatic population? bone
health
GCS are a mainstay of anti-asthmatic therapy. The current
consensus indicates that long term treatment with GCS is associ-
ated with detrimental effects on bone [64,273,283]. Further, both
airway hyper-responsiveness and asthma were related to clinically
meaningful decreased bone mineral density (BMD) in a recent
study of 7034 Korean individuals [123]. It is possible this finding
may be explained by concomitant GCS use.
VDI is associated with a decreased response to GCS and there-
fore greater use (reviewed above). Vitamin D is best known for its
beneficial effects of bone metabolism. During treatment with oral
corticosteroids (OCS), VDI has been associated with decreased bone
mineral accrual whereas vitamin D sufficiency seems to protect
asthmatic children from loss of bone calcium [292].
The combination of vitamin D3 (1,000 IU/day), calcium
(1,000 mg/day) and ethane-1-hydroxy-1,1-diphosphonate (0.5 mg/
kg body weight), has been shown to prevent decreases in BMD and
perhaps increase BMD [273]. Because of the combination of thera-
pies, it is impossible to assess the independent role of vitamin D
based on this preliminary study. However, the addition of 600 IU
vitamin D3/day to inhaled budesonide (400 mg/d) for 4 weeks to
asthmatic children did not affect short-term growth or markers of
bone despite a significant increase in serum 25(OH)D [225]. Simi-
larly, a subsequent DBRCT did notfind any benefit of 1,25D (0.5mcg/
day) on bone health [170]. A small DBRCT (n ¼ 62) of 50,000 IU
vitamin D/week þ 1,000 mg calcium/d in a diverse group of corti-
costeroid users demonstrated that although vitamin D þ calcium
blunted the initial decrease in BMD, there was no observable long-
term benefit and differences between vitamin D þ calcium vs. pla-
cebo did not reach statistical significance at any point [293]. How-
ever, the addition of 800 IU vitamin D3 daily to 24 weeks of steroid
therapy in children was associated with improvement in both cal-
ciumephosphorus balance and collagen turnover [240]. These dis-
crepancies may potentially be explained by serum 25(OH)D levels,
differing vitamin D dose and intervention period.
The CochraneDatabase of Systematic Reviews evaluated the data
supporting the recommendation to use calcium and vitamin D as
preventive therapy in patients receiving GCS [108]. The authors
concluded that because calciumand vitaminDhave low toxicity and
are inexpensive and that all patients starting GCS should also take a
calcium and vitamin D supplement prophylactically. Therefore, in
addition to any effect of vitamin D on asthma parameters, adequate
serum 25(OH)D may prove to be beneficial for bone health and
mitigate the effects of long term anti-asthmatic therapy. However,
further research is required among asthmatics to determine the
effect, if any, of vitamin D therapy on bone health in asthmatics.
4. Conclusions
It is clear that vitamin D influences diverse influences immu-
noregulatory and anti-inflammatory. To better understand the
relationship between vitamin D and asthma, data from human
studies is required. The second part of this two-part review sum-
marizes the existing epidemiological, case-control, cross-sectional,
prospective and intervention studies regarding asthma and vitamin
D [127].
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